↓ Skip to main content

Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study

Overview of attention for article published in Acta Medica Austriaca, December 2013
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
28 Mendeley
Title
Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study
Published in
Acta Medica Austriaca, December 2013
DOI 10.1007/s00508-013-0475-3
Pubmed ID
Authors

Josko Markic, Branka Polic, Luka Stricevic, Vitomir Metlicic, Radenka Kuzmanic-Samija, Tanja Kovacevic, Ivana Erceg Ivkosic, Julije Mestrovic

Abstract

Pompe disease is a storage disorder characterized by deficient or absent activity of the enzyme acid alpha-glucosidase. As a result of ineffective metabolism, glycogen accumulates in muscle tissues. Patients with a classic infantile-onset form present by the first few months of life with hypertrophic cardiomyopathy and muscle weakness. If left untreated, these patients rapidly die of cardiorespiratory failure. A cross-reactive immunological material (CRIM)-negative status is predictive of high anti-alglucosidase alpha antibody titers. However, CRIM-positive patients also sometimes develop robust antibody titers. High antibody titers complicate therapeutic management, and those patients have a worse clinical outcome of enzyme replacement therapy (ERT).Four years ago, we successfully used an immune modulation therapy (IMT) protocol in a CRIM-positive infantile-onset patient with Pompe disease in whom ERT had to be discontinued because of severe infusion-associated reactions. She was found to be positive for anti-alglucosidase alpha antibodies. IMT (rituximab, methotrexate, and intravenous gammaglobulin) was started, and ERT was safely reintroduced during the IMT induction phase without any complications. Antibodies disappeared; IMT was tapered and discontinued; and cardiomyopathy steadily improved. During more than 3 years of follow-up, she remained ventilator dependent, and no gains in motor skills were noticed. The antibodies are still undetectable, and no adverse reactions associated with IMT had occurred. The cardiomyopathy is gradually increasing, but there is still ~ 50 % reduction as compared with the highest value measured. Although the reversal of clinical decline in our CRIM-positive and antibody-positive infant cannot be solely attributed to IMT, this protocol proved itself efficient and safe.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 14%
Other 4 14%
Student > Doctoral Student 3 11%
Student > Bachelor 3 11%
Student > Master 3 11%
Other 4 14%
Unknown 7 25%
Readers by discipline Count As %
Medicine and Dentistry 11 39%
Biochemistry, Genetics and Molecular Biology 2 7%
Linguistics 1 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Psychology 1 4%
Other 3 11%
Unknown 9 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 December 2013.
All research outputs
#22,758,309
of 25,373,627 outputs
Outputs from Acta Medica Austriaca
#836
of 967 outputs
Outputs of similar age
#282,813
of 321,418 outputs
Outputs of similar age from Acta Medica Austriaca
#5
of 7 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 967 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,418 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.